Core Viewpoint - The Tsinghua University Yuquan Hospital team has introduced an innovative "Disease-Brain-Body" three-dimensional integrated treatment system for Parkinson's disease, marking a shift from symptom-based treatment to a systematic and precise approach [1][2]. Group 1: Treatment Framework - The "Disease-Brain-Body" system aims to address the limitations of traditional treatment methods by providing a comprehensive framework that includes three key dimensions: disease assessment, brain evaluation, and body condition [1][2]. - The team developed the DM motion assessment system to quantify motor symptoms like tremors and rigidity, providing objective biomarkers for treatment [1]. - HEMA multimodal imaging technology allows for individualized assessment of brain functional networks, enhancing the precision of deep brain stimulation (DBS) surgery [2]. Group 2: Clinical Application and Benefits - The new system demonstrates three significant advantages: precise diagnosis through multidimensional assessment, personalized treatment plans driven by data rather than experience, and a comprehensive management model that ensures continuous optimization of treatment outcomes [2]. - The integration of traditional Chinese medicine principles into the treatment framework aims to improve overall patient functionality by balancing bodily systems [2]. Group 3: Future Directions - The team plans to explore new clinical and research directions, including the use of big data and artificial intelligence for intelligent diagnosis, establishing more refined disease classifications based on multi-omics data, and updating industry treatment standards through evidence-based research [3].

Core Viewpoint - The article highlights the significant milestone achieved by United Imaging Healthcare with the approval and launch of its uSONIQUE series of color Doppler ultrasound diagnostic systems, marking a transition from high-end imaging equipment manufacturing to a comprehensive intelligent diagnostic platform [1][5][25]. Summary by Sections Product Approval and Launch - On November 11, 2025, United Imaging's subsidiary received three medical device registration certificates from the National Medical Products Administration (NMPA) for its self-developed color Doppler ultrasound diagnostic systems [1][5]. - The subsequent global ultrasound product launch occurred on November 12, showcasing the uSONIQUE series, which took six years to develop [1][5]. Product Range and Market Coverage - The approved ultrasound systems include three series: uSONIQUE Pulse (ultra-high-end), uSONIQUE Genesis (high-end), and uSONIQUE Venus (mid-range/economic), creating a complete market coverage matrix [3][5]. - These products are applicable in various clinical scenarios, including cardiology, obstetrics, and emergency care [3]. Technological Innovations - The uSONIQUE series is built on the uEDGETEC intelligent perception technology platform, integrating AI throughout the hardware and algorithmic processes [8]. - Key innovations include the AIClear real-time intelligent noise reduction algorithm, which significantly improves imaging quality for challenging patients [12]. - The AIStream workflow automates the entire process from probe activation to report generation, reducing scan time by approximately 88% [14]. Strategic Significance - The launch of the ultrasound business is seen as a crucial addition to United Imaging's "imaging-diagnosis integration ecosystem," completing its portfolio that already includes CT, MRI, and PET technologies [20][22]. - The company aims to enhance its international competitiveness and fill the gap in the high-frequency, high-resolution imaging market, where domestic market penetration is currently low [23][24]. Global Expansion Plans - United Imaging plans to unveil the global version of the uSONIQUE series at the 2025 RSNA conference, accelerating its FDA certification and market expansion in Europe and the U.S. [24]. - The company leverages its established global brand and channel resources to lead the domestic high-end ultrasound market [23].

Core Viewpoint - The third National Postdoctoral Innovation and Entrepreneurship Competition has launched a "Challenge and Lead" project list, featuring 766 technology projects that seek participation from postdoctoral researchers and teams [1][2]. Group 1: Competition Overview - The competition is the largest and most comprehensive postdoctoral event in China, aimed at promoting the integration of industry, academia, and research [1]. - The "Challenge and Lead" segment invites enterprises to present technical challenges, which postdoctoral researchers are encouraged to solve [1]. Group 2: Project Details - A total of 766 project demands have been released, focusing on four key areas aligned with national strategies and cutting-edge scientific technologies, with a total planned investment exceeding 40 billion yuan [2]. - The projects cover seven major directions, including new generation information technology and artificial intelligence, high-end equipment manufacturing, and robotics [2]. - The top areas of demand include: - New generation information technology and artificial intelligence: 143 projects (18.7%) - Biomedicine and health: 140 projects (18.3%) - New materials and petrochemicals: 135 projects (17.6%) - High-end equipment manufacturing and robotics: 131 projects (17.1%) - New energy and energy conservation: 93 projects (12.1%) - Modern agriculture and food: 67 projects (8.7%) - Other industries: 57 projects (7.4%) [2]. Group 3: Participation and Timeline - The project list has been publicly released on various platforms, including the China Postdoctoral website and the official competition website [3]. - The registration deadline for participation is July 31, 2025, with successful teams invited to the finals in Quanzhou, Fujian Province, in mid to late October [3].